BCM
NVCR icon

Bridgeway Capital Management’s NovoCure NVCR Stock Holding History

Bridgeway Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-23,080
Closed -$2.68M – 1308
2021
Q3 		$2.68M Buy
23,080
+12,200
+112% +$1.84M 0.05% 504
2021
Q2 		$2.41M Buy
+10,880
New +$2.12M 0.04% 548

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management's NVCR Position: Q4 2021 in Review

Bridgeway Capital Management sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 23,080 shares — an estimated $2.68M sold.

Bridgeway Capital Management first reported a position in NVCR in Q2 2021 and held it in 2 quarters. The position peaked at $2.68M in Q3 2021. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

  • Bridgeway Capital Management reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
  • Bridgeway Capital Management sold 23,080 NovoCure shares in Q4 2021, an estimated $2.68M.
  • Bridgeway Capital Management first reported a position in NovoCure in Q2 2021 and held it in 2 quarters.
  • Bridgeway Capital Management's NovoCure position peaked at $2.68M in Q3 2021.
  • 311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Bridgeway Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.